Comparison of standard immunosuppression with adjuvant antilymphoblast globulin in primary cadaver kidney transplant survival

John Barry, Elizabeth Frankus, Douglas Norman, William M. Bennett

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Adjuvant, prophylactic, antilymphoblast globulin and standard immunosuppression have produced comparable long-term cadaver kidney graft survivals at separate institutions. A comparison was made of 35 primary cadaver kidney grafts into recipients treated with prophylactic, adjuvant antilymphoblast globulin to 55 recipients of primary cadaver kidney grafts treated with standard immunosuppression. Antilymphoblast globulin delayed early rejection episodes (P under 0.05), making early post-transplant management simpler. There were no significant differences between the two groups with respect to graft losses due to rejection at any interval beyond one month.

Original languageEnglish (US)
Pages (from-to)287-289
Number of pages3
JournalUrology
Volume19
Issue number3
DOIs
StatePublished - 1982

Fingerprint

Antilymphocyte Serum
Cadaver
Immunosuppression
Transplants
Kidney
Graft Survival

ASJC Scopus subject areas

  • Urology

Cite this

Comparison of standard immunosuppression with adjuvant antilymphoblast globulin in primary cadaver kidney transplant survival. / Barry, John; Frankus, Elizabeth; Norman, Douglas; Bennett, William M.

In: Urology, Vol. 19, No. 3, 1982, p. 287-289.

Research output: Contribution to journalArticle

@article{c0bce0f7372c47938023b304e61fc474,
title = "Comparison of standard immunosuppression with adjuvant antilymphoblast globulin in primary cadaver kidney transplant survival",
abstract = "Adjuvant, prophylactic, antilymphoblast globulin and standard immunosuppression have produced comparable long-term cadaver kidney graft survivals at separate institutions. A comparison was made of 35 primary cadaver kidney grafts into recipients treated with prophylactic, adjuvant antilymphoblast globulin to 55 recipients of primary cadaver kidney grafts treated with standard immunosuppression. Antilymphoblast globulin delayed early rejection episodes (P under 0.05), making early post-transplant management simpler. There were no significant differences between the two groups with respect to graft losses due to rejection at any interval beyond one month.",
author = "John Barry and Elizabeth Frankus and Douglas Norman and Bennett, {William M.}",
year = "1982",
doi = "10.1016/0090-4295(82)90501-5",
language = "English (US)",
volume = "19",
pages = "287--289",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Comparison of standard immunosuppression with adjuvant antilymphoblast globulin in primary cadaver kidney transplant survival

AU - Barry, John

AU - Frankus, Elizabeth

AU - Norman, Douglas

AU - Bennett, William M.

PY - 1982

Y1 - 1982

N2 - Adjuvant, prophylactic, antilymphoblast globulin and standard immunosuppression have produced comparable long-term cadaver kidney graft survivals at separate institutions. A comparison was made of 35 primary cadaver kidney grafts into recipients treated with prophylactic, adjuvant antilymphoblast globulin to 55 recipients of primary cadaver kidney grafts treated with standard immunosuppression. Antilymphoblast globulin delayed early rejection episodes (P under 0.05), making early post-transplant management simpler. There were no significant differences between the two groups with respect to graft losses due to rejection at any interval beyond one month.

AB - Adjuvant, prophylactic, antilymphoblast globulin and standard immunosuppression have produced comparable long-term cadaver kidney graft survivals at separate institutions. A comparison was made of 35 primary cadaver kidney grafts into recipients treated with prophylactic, adjuvant antilymphoblast globulin to 55 recipients of primary cadaver kidney grafts treated with standard immunosuppression. Antilymphoblast globulin delayed early rejection episodes (P under 0.05), making early post-transplant management simpler. There were no significant differences between the two groups with respect to graft losses due to rejection at any interval beyond one month.

UR - http://www.scopus.com/inward/record.url?scp=0020041281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020041281&partnerID=8YFLogxK

U2 - 10.1016/0090-4295(82)90501-5

DO - 10.1016/0090-4295(82)90501-5

M3 - Article

C2 - 7039064

AN - SCOPUS:0020041281

VL - 19

SP - 287

EP - 289

JO - Urology

JF - Urology

SN - 0090-4295

IS - 3

ER -